Pluristem, a CLI company, or a Stem Cell Technology company ??
I believe it's the latter! As painful as this much anticipated result turned out to be, it's important to remember that CLI is (was) one specific instance of the general notion that (placental) stem cells have the potential to give us novel, high quality therapeutics.
This particular POC would have placed us on the map very convincingly and would have proven very profitable for the company and investors. The fact that it did not work out that way does not change the basic proposition (in terms of the technology).
Pluristem has accumulated an enormous amount of knowledge (production, distribution, regulatory) and a huge patent portfolio, not to mention a strong presence in the medical/scientific community. All of that is of significant advantage going forward.
The question remains on whether Pluristem can deliver a product with its remaining resources, and when. I'm optimistic on the continuing opportunities for the company. There is huge interest and scientific activity in this arena. My sense is that Pluristem is going to be able to capitalize on it's accumulated experience to come back. We do need just one success story to put us back on the right path. My hope is that the Covid effort will show that the cells are able to respond to the body's distress signals and thus prove the utility of the approach (even if Covid is "cured" by then).
I'm sticking around to see how it turns out, but whatever others decide, wishing all the best,
zzaatt.
